ScholarLens Back to search
2007•Zhongguo yiyuan yongyao pingjia yu fenxiRequires access

Aripiprazole vs. Risperidone for Schizophrenia:A Controlled Study

Tian Peiyao

Open publisher page 0 citations

Abstract

OBJECTIVE:To discuss the efficacy and side effects of aripiprazole in the treatment of schizophrenia.METHODS: 30 schizophrenic patients were assigned to receive risperidone(control group) and another 30 to receive aripiprazole(trial group),with efficacy evaluated by the positive and negative symptoms scale(PANSS) and the adverse events evaluated by the treatment emergent symptoms scale(TESS).RESULTS: There were significant differences between two groups in total PANSS scores at endpoint as compared with the baseline(P0.01).The responsive rate and excellent effective rate in aripiprazole group were 93% and 83%,respectively,and those in risperidone group were 90% and 80%,respectively,showing no significance in efficacy between two groups(P0.05).The incidence of side effects was higher in risperidone group than in aripiprazole group.CONCLUSION: Aripiprazole has been proved to be an effective and safe therapy for schizophrenia.

About this research paper

What this paper is about

OBJECTIVE:To discuss the efficacy and side effects of aripiprazole in the treatment of schizophrenia.METHODS: 30 schizophrenic patients were assigned to receive risperidone(control group) and another 30 to receive aripiprazole(trial group),with efficacy evaluated by the positive and negative symptoms scale(PANSS) and the adverse events evaluated by the treatment emergent symptoms scale(TESS).RESULTS: There were significant differences between two groups in total PANSS scores at endpoint as compared with the baseline(P0.01).The responsive rate and excellent effective rate in aripiprazole group were 93% and 83%,respectively,and those in risperidone group were 90% and 80%,respectively,showing no significance in efficacy between two groups(P0.05).The incidence of side effects was higher in risperidone group than in aripiprazole group.CONCLUSION: Aripiprazole has been proved to be an effective and safe therapy for schizophrenia.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE:To discuss the efficacy and side effects of aripiprazole in the treatment of schizophrenia.METHODS: 30 schizophrenic patients were assigned to receive risperidone(control group) and another 30 to receive aripiprazole(trial group),with efficacy evaluated by the positive and negative symptoms scale(PANSS) and the adverse events evaluated by the treatment emergent symptoms scale(TESS).RESULTS: There were significant differences between two groups in total PANSS scores at endpoint as compared with the baseline(P0.01).The responsive rate and excellent effective rate in aripiprazole group were 93% and 83%,respectively,and those in risperidone group were 90% and 80%,respectively,showing no significance in efficacy between two groups(P0.05).The incidence of side effects was higher in risperidone group than in aripiprazole group.CONCLUSION: Aripiprazole has been proved to be an effective and safe therapy for schizophrenia.

Key concepts: Aripiprazole, Risperidone, Schizophrenia (object-oriented programming), Positive and Negative Syndrome Scale, Medicine, Internal medicine, Adverse effect, Psychology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Aripiprazole vs. Risperidone for Schizophrenia:A Controlled Study — Research Paper | ScholarLens